Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Intervacc

Intervacc

Read in Swedish

Report from Annual General Meeting in Intervacc

20:30 / 14 June 2022 Intervacc Press release

Intervacc AB (publ) has held its Annual General Meeting ("AGM") on Tuesday 14 June 2022, at which the following resolutions were made.

Adoption of the income statement and balance sheet

The AGM adopted the Board of Directors' submitted income statement and balance sheet for the parent company and the group for the financial year 2021.

Appropriation of the company's profit or loss

The AGM resolved, in accordance with the Board of Directors' proposal, that no dividend shall be paid for the financial year 2021, and that the result shall be balanced in a new account.

Discharge from liability towards the members of the Board of Directors and the CEO

The AGM resolved to discharge each of the members of the Board of Directors and the CEO from liability for the financial year 2021.

Board of Directors and auditor

The AGM resolved, in accordance with the Nomination Committee's proposal, that the Board of Director shall consist of seven Board members without any deputies.

The AGM resolved, in accordance with the Nomination Committee's proposal, to re-elect Bengt Guss, Marianne Hansson, Stefan Ståhl, Niels Holck, Björn Sjöstrand and Ed Torr, and to elect Michela de Carli, as Board members. Björn Sjöstrand was re-elected as the Board of Directors' chairperson.

The AGM resolved, in accordance with the Nomination Committee's proposal, that the fees to the Board of Directors shall be paid with SEK 280,000 to the Board of Directors' chairperson and SEK 130,000 to each of the other Board members.

The AGM resolved, in accordance with the Nomination Committee's proposal, to re-elect the registered public accounting firm Öhrlings PricewaterhouseCoopers AB as the company's auditor for the period up to and including the next AGM, which intends to appoint the Authorised Public Accountant Leonard Daun as auditor in charge.

The AGM resolved that fees to the auditor shall be paid according to the current account.

Guidelines for appointment of Nomination Committee and instructions for the Nomination Committee

The AGM resolved, in accordance with the Nomination Committee's proposal, that the Nomination Committee, prior to the next AGM, shall consist of the three largest shareholders or group of owners as of the last banking day in August.

Authorisation regarding issues

The AGM resolved, in accordance with the Board of Directors' proposal, to authorise the Board of Directors, within the limits of the Articles of Association, with or without deviation from the shareholders' preferential rights, on one or more occasions, until the next AGM, to resolve to increase the company's share capital through issues of new shares, warrants and/or convertibles in the company. The total number of shares covered by such new issues may correspond to a total of no more than ten (10) percent of the shares in the company at the time of the AGM 2022.

Amendment of the Articles of Association

The AGM resolved, in accordance with the Board of Directors' proposal, to introduce a new Section in the Articles of Association that allows the Board of Directors to collect proxies in accordance with the procedure set out in Chapter 7, Section 4 of the Swedish Companies Act and which also enables the Board of Directors to resolve that shareholders shall be able to exercise their voting rights by voting by post before the General Meeting in accordance with what is set out in Chapter 7, Section 4a of the Swedish Companies Act.

For more information please contact:

Andreas Andersson, CEO

Phone: +46 (0)8 120 10601, Cell: +46 (0)73 335 99 70

E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on June 14, 2022, 20.30 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the NASDAQ First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se,+46(0)8-68421110 as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10

Show as PDF

Show original from Cision

Cision

This information was distributed by Cision http://www.cisionwire.se/